Navigation Links
FDA Issues Guidance to Help Streamline Medical Device Clinical Trials
Date:2/5/2010

Agency says Bayesian statistical methods could trim costs, boost efficiency

SILVER SPRING, Md., Feb. 5 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today issued guidance on Bayesian statistical methods in the design and analysis of medical device clinical trials that could result in less costly and more efficient patient studies.

(Logo: http://www.newscom.com/cgi-bin/prnh/20090824/FDALOGO)

The Bayesian statistical method applies an algorithm that makes it possible for companies to combine data collected in previous studies with data collected in a current trial. The combined data may provide sufficient justification for smaller or shorter clinical studies.

"This final guidance on the use of Bayesian statistics is consistent with the FDA's commitment to streamline clinical trials, when possible, in order to get safe and effective products to market faster," said FDA Commissioner Margaret A. Hamburg, M.D. "This is a terrific example of regulatory science in practice at FDA."

The FDA has substantial experience in the use of Bayesian statistical methods for the design and analysis of scientifically valid clinical studies. The FDA has approved a number of medical devices whose approval applications submitted to the FDA included clinical studies that used these statistical methods.

The final guidance, titled "Guidance for the Use of Bayesian Statistics in Medical Device Clinical Trials," describes use of Bayesian methods, design and analysis of medical device clinical trials, the benefits and difficulties with the Bayesian approach, and comparisons with standard statistical methods. The guidance also presents ideas for using Bayesian methods in post-market studies.

The final document reflects public input gathered in 2006 after release of a draft of the guidance.

Health care payers are also contemplating the role Bayesian methods could play in making coverage decisions. In a June 2009 public meeting, the Medicare Evidence Development & Coverage Advisory Committee encouraged Medicare policymakers to consider Bayesian approaches when reviewing trials or technology assessments during the national coverage analysis process.

Guidance for Use of Bayesian Statistics in Medical Device Clinical Trials

http://fda.gov/FDAgov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/ucm071072.htm?SSContributor=true

For more information about Medicare's national coverage analysis process

http://www.cms.gov/coveragegeninfo/

Media Inquiries: Karen Riley, 301-796-4674; karen.riley@fda.hhs.gov  

Consumer Inquiries: 888-INFO-FDA

SOURCE U.S. Food and Drug Administration

RELATED LINKS
http://www.fda.gov/
http://www.cms.gov/coveragegeninfo/

'/>"/>

SOURCE U.S. Food and Drug Administration
Copyright©2010 PR Newswire.
All rights reserved

Related medicine news :

1. Older female cancer survivors have added health issues compared to their counterparts
2. NVHR Issues Challenge to Administration, Congress: Dont Leave 5 Million Americans Afflicted with Chronic Viral Hepatitis Out in the Cold with Budget Freeze
3. Operation Rescues Advisory Board Issues Statement on Mr. Terrys Extremism
4. Greenfaith Ministry Calls on Churches & Doctors, to Address all Cannabis Issues and Regulation
5. School Support Lacking for Emotional, Behavioral Issues, say Parents
6. APS Healthcare Issues First Award to South Carolina Providers Using Data to Increase Effectiveness of Mental Health Treatment
7. Largest RN Union Issues Urgent Call for Nurse Volunteers to Assist Earthquake Ravaged Haiti
8. National Council on Disability to Hold Houston Meeting to Hear Issues Affecting People With Disabilities
9. Phyhealth Issues September 30, 2009 Financial Statements
10. Squeezing Costs out of Healthcare Tops PricewaterhouseCoopers List of Health Industry Issues in 2010
11. Half of U.S. Kids With Mental Issues Are Getting Help
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/7/2016)... Birmingham, Lake Orion, Clarkston, Metamora, Michigan (PRWEB) , ... ... ... the ability to correct pelvic organ prolapse with the latest techniques and the ... at greatest risk for pelvic organ prolapse, particularly after menopause. Other risk factors ...
(Date:2/7/2016)... ... 2016 , ... HealthSmart Holdings, Inc. announced today the launch ... and information to lower the costs, and increase the impact of their healthcare ... healthcare benefits by as much as 22%:, + Price and quality transparency, ...
(Date:2/6/2016)... ... February 06, 2016 , ... ... PERIOPERATIVE NURSES EXPECTED AT AORN SURGICAL CONFERENCE & EXPO , WHAT:     , ... with an estimated 5000 perioperative nurses in attendance to study the latest ...
(Date:2/6/2016)... , ... February 06, 2016 , ... With the ... add warm color grades to their footage. A LUT is a Lookup Table that ... to the corresponding color indicated by the table. By manipulating each pixel, LUT's can ...
(Date:2/6/2016)... ... 06, 2016 , ... Research has shown that building shame ... frequency and level of relapse. , At the 2016 iaedp Symposium, ... explore the critical tasks of the recovery phase and beyond including relapse prevention ...
Breaking Medicine News(10 mins):
(Date:2/4/2016)... 4, 2016 Wegener Polyangiitis - Pipeline ... Direct,s, ,Wegener Polyangiitis - Pipeline Review, H2 2015, ... pipeline. This report provides comprehensive information on ... comparative analysis at various stages, therapeutics assessment by ... administration (RoA) and molecule type, along with latest ...
(Date:2/4/2016)... 2016 Frontier Pharma: Chronic Obstructive Pulmonary ... Chronic Obstructive Pulmonary Disease (COPD) ... of the airways and lungs. Persistent breathing difficulties ... disease one of the leading causes of morbidity ... world. COPD is linked to cumulative exposure to ...
(Date:2/4/2016)... -- In response to the opioid abuse epidemic, today Dr. ... Products and Tobacco, along with other FDA leaders, called for ... opioid medications. The plan will focus on policies aimed at ... to effective relief. --> ... risk-benefit paradigm for opioids and ensure that the agency considers ...
Breaking Medicine Technology: